|Year : 2016 | Volume
| Issue : 2 | Page : 447-457
Clinical significance of inflammatory mediators in the pathogenesis of oral cancer
Jayendrakumar B Patel1, Franky D Shah1, Geeta M Joshi2, Prabhudas S Patel1
1 Biochemistry Research Division, The Gujarat Cancer and Research Institute, Ahmedabad, India
2 Deputy Director, The Gujarat Cancer and Research Institute, Ahmedabad, India
|Date of Web Publication||25-Jul-2016|
Prabhudas S Patel
Head, Department of Cancer Biology, The Gujarat Cancer and Research Institute, Asarwa, Ahmedabad - 380 016, Gujarat
Source of Support: None, Conflict of Interest: None
Oral cancer has become a grave problem in many parts of the globe with two.thirds of the cases occurring in developing countries. Chronic inflammation plays a prominent role in the development of oral cancer. The rationale for molecular targeted prevention of oral cancer is promising. Therefore, there are continued improvements to our understanding of the molecular connections between inflammation and oral cancer. The inflammatory mediators including nuclear factor kappa B, vascular endothelial growth factor, inflammatory cytokines, prostaglandin pathways, p53, reactive oxygen and nitrogen species, and microRNAs are major key players in the pathogenesis of oral cancer. Currently, visual cytology.based techniques and biopsy are used to detect dysplasia and early stage of oral squamous cell carcinoma. These approaches are limited in their ability to judge the severities of oral lesions and are useful only after the appearance of visual changes. Thus, traditional cytological and biopsy assays combined with testing of inflammatory biomarkers would be beneficial for the efficient early detection of oral dysplastic lesions and early stages of oral squamous cell carcinoma.
Keywords: Inflammation, molecular signature, oral cancer
|How to cite this article:|
Patel JB, Shah FD, Joshi GM, Patel PS. Clinical significance of inflammatory mediators in the pathogenesis of oral cancer. J Can Res Ther 2016;12:447-57
| > Introduction|| |
Oral cancer is a major cause of morbidity and mortality worldwide. Annually 400,000 new cases of oral cancer annually have been detected in the world., Oral cancer is also a major health problem in the Indian subcontinent. It is the commonest cancer in the Southeast Asia and in India., Moreover, in western countries, it is only 3-5% of total cancers. In India, its incidence is particularly high and is frequently associated with habit of chewing paan mixed with tobacco, which contains areca nut-based carcinogens. Millions of people in India are exposed to tobacco smoke or smokeless tobacco products.
Oral cancer is a multi-step process with a multifactorial etiology especially involving tobacco and alcohol use and various genetic changes. Advances in understanding of mechanism of oral carcinogenesis are necessary to improve survival curves that plateaued over the past two decades have remained among the worst of all cancer sites., Many research studies involving the detection of oral cancer have been conducted; however, their findings are far from being applied in the clinical setting. Currently, cytological testing is the most common mode of detection. Although various light-based visual examinations of the oral cavity have been proposed for screening oral lesions in recent decades, these techniques exhibit several limitations. Whereas, biochemical and molecular assays involving the oral mucosa show the greatest potential for overcoming diagnosis related limitations and would serve as excellent gold standards. It is important and necessary to apply the vast knowledge that has been obtained regarding inflammatory mediators in oral cancer in the clinical area.
Inflammation is the major hallmark of cancer. As early as in the 19th century it was perceived that cancer is linked to inflammation. This perception has waned for a long time. Previous reports have seen a renaissance of the inflammation cancer connection stemming from different lines of work and leading to generally accepted paradigm. Epidemiological studies have revealed that the chronic inflammation play prominent role in the development of oral cancer. Therefore, there are continued improvements to our understanding of the molecular connections between inflammation and oral cancer. Inflammatory mediators including nuclear factor kappa B (NF-κB), vascular endothelial growth factor (VEGF), inflammatory cytokines, prostaglandins, p53, nitric oxide (NO), reactive oxygen species (ROS) and nitrogen species, and specific microRNAs (miRNAs) are major key players in pathogenesis of oral cancer. The expression of these mediators is largely responsible for either a pro-tumorigenic or anti-tumorigenic inflammatory response through changes in cell proliferation, cell death, cellular senescence, DNA mutation, DNA methylation and angiogenesis. Understanding of these will provide opportunities to develop novel diagnostic and therapeutic strategies , [Figure 1]. The present review summarize the reports on clinical significance of potential inflammatory associated molecular signature for early detection of oral dysplasia and squamous cell carcinoma.
|Figure 1: Chronic inflammation alters the cellular levels of inflammatory mediators|
Click here to view
| > Nuclear Factor Kappa B and Oral Cancer|| |
Nuclear factor kappa B is a ubiquitous nuclear transcription factor mapped on chromosome 11q13 that was first identified in 1986 by Sen and Baltimore. It was named by its location in the nucleus and bounded to an 11-base pair sequence in the enhancer element of the immunoglobulin kappa light chain gene in B cells. It represents a group of structurally related proteins, with five members in mammals forming dimers by combination of several proteins including NF-κB p65 (Rel A). Consistent with its role in inflammatory and immune response, incorrect regulation of NF-κB has been linked to activation of oncogenes, cytokine receptors, cell adhesion molecules and growth factors [Figure 2]. NF-κB is activated by ROS, cytokines, viruses, protein kinase C activators and immunological stimuli. In most cells NF-κB/Rel proteins are sequestered in the cytoplasm, bound to IKBs. Upon stimulation of cells by inducers such as interleukin 1 beta (IL-1β) and tumor necrosis factor alpha (TNF-α), IKBs are degraded and NF-κB is translocated to the nucleus where it modulates the expression of genes involved in inflammation, extracellular matrix degradation, cell adhesion, angiogenesis and prevention of cell death. Activation of NF-κB involves phosphorylation, followed by ubiquitination and proteosome mediated degradation of IKBs. NF-κB suppression in combination with chemotherapeutic agents is found to be useful for the adequate treatment of human salivary gland malignancies., Moreover, it has been reported that aberrant activation of NF-κB occurs in human malignant cells and that specific inhibition of activity leads to apoptosis. It has been also documented that inhibition of NF-κB may provide a means of intervention at early as well as later stages of the transformation process in the mammary gland. There are increasing evidences that the NF-κB/Rel family is important in controlling cell proliferation and oncogenesis. Based on recent reports [Table 1], it is hypothesized that exposure to tobacco carcinogens stimulate proinflammatory activity of human monocytes through activation of NF-κB.
| > Vascular Endothelial Growth Factor and Oral Cancer|| |
Oral cancer cells with different potential of lymphatic metastasis displayed distinct biological behaviors and gene expression profiles. Angiogenesis plays an important role in tumor growth and prognosis. Primary tumor cannot grow beyond 3 mm without new vessel formation. A key angiogenesis stimulator is VEGF, which promotes vessel permeability, cell proliferation and migration of endothelial cells and inhibits apoptosis. VEGF overproduction by a wide spectrum of tumor cells suggested that this angiogenic factor plays an important role in tumorigenesis. Expression of VEGF was an independent prognostic factor in patients with breast cancer, colon cancer and esophageal squamous cell carcinoma. A tumor specimen from cancer patients showed an association between poor prognosis and/or low survival rates and VEGF overexpression. As documented recently [Table 2], there is a strong evidence for the contribution of VEGF to the progressive growth of solid tumors through its effect on promoting tumor angiogenesis. Furthermore, when VEGF signaling is inhibited, tumor angiogenesis and consequently, tumor growth are impaired.
| > Interleukin-8 and Oral Cancer|| |
Previous studies of in vitro human cell lines as well as malignant tumors have demonstrated that concentration of certain proinflammatory, proangiogenic cytokines such as TNF-α, IL-1, IL-6, and IL-8 are increased in oral cancer., It has been known that cellular genes including IL are uniquely associated with oral squamous cell carcinoma. These cytokines have also been linked with increased tumor growth and metastasis, and could thus contribute to the pathogenesis of oral disease. Elevated concentrations of IL-8 in cell line supernatants, tumor specimens, and the serum of patients with oral squamous cell carcinoma have also been documented. Recent studies [Table 3] have documented that salivary levels, as well as gene polymorphisms of IL-8 and environmental carcinogens, might be highly related to the risk of oral cancer. Therefore, it is important to study association between inflammation and oral squamous cell carcinoma development through the potential mediator, IL-8.
| > Prostaglandin Molecular Pathway and Oral Cancer|| |
The smoke or smokeless products contain thousands of chemical constituents including major alkaloid (nicotine) and minor alkaloids (noricotine, anabasine, anatabine, etc). The formation of tobacco specific nitrosamines like 4-(methyl nitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and 4-(methyl nitrosamino)-1-(3-pyridyl)-1-butanol occur from nicotine, nornicotine, anabasine by the reaction with nitrite. NNK bioactivation leads to the production of ROS, which are known to activate NF-κB that acts as positive regulatory element of cyclooxygenase (COX)-2 expression ,, [Figure 3]. Both, COX-1 and COX-2 are the key enzymes in the synthesis of prostaglandins. They catalyze the same reaction of arachidonic acid to prostaglandin 5-hydroxy analogue. The two forms of COX, COX-1 and COX-2 have different biological role. The constitutively expressed COX-1 is known to carry out “housekeeping” functions including the production of prostaglandin under normal physiological conditions. In contrast, the COX-2 protein is normally absent in most tissues. COX-2 expression can be induced by inflammatory mediators including cytokines mitogens, growth factors, oncogenes and carcinogens. Over expression of COX-2 is seen in several neoplastic tissues including oral cancer. Previous reviews , have explained that COX-2 metabolized NNK more effectively than COX-1. It has been suggested that ingredients of areca nut play a critical role in the pathogenesis of oral submucous fibrosis and oral cancer via their stimulatory effects on the prostagalndin through COX-2 production and associated tissue inflammatory responses. Recent reports [Table 3] have indicated that chronic inflammation is one of the characteristics of oral lichen planus. COX-2 is an important molecule showing close relation to inflammation, carcinogenesis and angiogenesis.
|Figure 3: Pathway of cyclooxygenase induction by 4-(methyl nitrosamino)-1-(3-pyridyl)-1-butanone in U937 macrophages|
Click here to view
| > P53 Expression and Oral Cancer|| |
p53 is the most widely studied tumor suppressor gene in a wide variety of solid tumors. The wild-type p53, a 53 kD short-lived nuclear phosphoprotein, is essential for normal cell growth and eventual suppression of a malignant phenotype. Inactivation of p53 induces development of malignancy. The mutant p53 loses its anti-proliferative properties favoring a deregulation of cellular multiplication with the accumulation of genetic aberrations. Mutations stabilize the p53 protein and extend its half-life to such an extent that may trigger humoral immune reaction releasing anti-p53 antibodies into the circulation. Recent reports suggest [Table 4] that expression of p53 would be a valuable tool for the study of early events in oral carcinogenesis.
| > Nitric Oxide and Oral Cancer|| |
The discovery in 1987 that NO accounted for the bioactivity of endothelium-derived relaxing factor, rapidly led to an explosion of information on the physiological and pathological role of this molecule. Half-life of NO is very short (3-30 s). It is an inorganic free radical gas, containing an odd number of electrons and can form a covalent link with other molecules by sharing a pair of electrons. NO is generated from the terminal guanido nitrogen atom of L-arginine by various NADPH dependent enzymes called NO synthase (NOS) located in various tissues, and play an active role in free radical and tumor biology., The three main isoforms of NOS are neuronal (nNOS), inducible (iNOS) and endothelial (eNOS). In general, nNOS and eNOS are expressed constitutively in neurons and endothelial cells, respectively, while; iNOS are expressed during pathogenesis of several diseases.
Nitric oxide has mutagenic properties. Long-term exposure of cells to high NO concentrations resulting from iNOS induction during chronic inflammation have an active role in carcinogenesis., Mutagenesis by NO can occur through several mechanisms , [Figure 4]. DNA damage due to deamination of nucleic acid bases has been shown in cell-free systems, bacteria, and macrophages. Transition and/or transversion of nucleic acid bases (e.g. G: C→ A:T, G: C→C: G, G: C.→ C: G, G: C→ A:T) by reactive NO products has been documented in plasmid DNA. Further, inactivation of DNA repair enzymes (e.g. alkyltransferase and DNA ligase) can occur owing to the high affinity of reactive NO species for amino acids containing thiol residues. It has been reported that NO may promote carcinogenesis by inactivating the tumor suppressor oncoprotein p53. Cells are containing wild-type p53, when exposed to excess NO, accumulated p53 protein with a concomitant loss of its DNA binding activity. This has been attributed to nitration of tyrosine residues in the protein. Further, mutation of p53 may occur in a high NO environment. A positive correlation between total NOS activity and the prevalent form of p53 mutation (G: C→ A: T at CpG dinucleotides) was reported in 27 head and neck carcinoma. Recent reports [Table 4] have shown that high production of NO through iNOS expression have a significant role in oral carcinogenesis.
| > Reactive Oxygen Species and Oral Cancer|| |
The free radicals generated during chewing and smoking of tobacco causes oxidative stress, which has been defined as a disturbance in the balance between the production of ROS and antioxidants defenses. The ROS damages various cellular targets including DNA, proteins and lipids, which leads to tissue injury. Cellular antioxidant enzymes normally protect the cells from toxic effects of the ROS. Hence, defensive mechanisms play a vital role in etiology of oral cancer. The first line of defense; antioxidants enzymes are superoxide dismutase (SOD) and catalase. SOD converts O2 − to H2O2, which is converted to H2O with the help of catalase. SOD and catalase are potent enzymatic antioxidants known to play an important role in combating oxidative stress. These antioxidants help in quenching the free radicals and ROS, produced during detoxification or in response to carcinogen exposure. Besides, second line of defense; detoxification pathway enzymes like glutathione-S-transferase (GST) including GSTM1 and GSTT1 and glutathione reductase (GR) also play important role in determining individual's susceptibility to develop oral cancer , [Figure 5]. Glutathione is also an important antioxidant. Biothiols, the major components of GSH, are extraordinarily efficient antioxidant, protecting the cell against consequence of damage-induced by free radicals. Recent reports [Table 5] have documented that genetic susceptibility is considered as one of the factors responsible for pathogenesis of oral cancer.
|Figure 5: (a) Prevention against reactive oxygen species by antioxidant enzymes (b) susceptibility to oral cancer against tobacco carcinogen compounds|
Click here to view
|Table 5: Significance of antioxidants/detoxification enzymes in oral cancer|
Click here to view
| > Micornas as Mediators of Inflammation in Oral Cancer|| |
MicroRNAs are a recently discovered class of regulatory molecules that have a convincing role in inflammation and cancer. miRNAs regulate the translation of specific genes. The first miRNAs, Lin-4 was discovered in cenorhabdits elegans in 1993 and was found to regulate development timing and cell fate specification. In 2000, miRNAs were found to be conserved in vertebrates and over the last decade miRNAs have been shown to be involved in nearly every cellular and development process examined.
MicroRNAs are short, noncoding RNA molecules (22 nucleotides) that bind the to 3'UTR of mRNA and regulate posttranscriptional gene expression in many cancers, including oral squamous cell carcinoma. Increased plasma miRNA (miR-31) has been previously reported in association with oral squamous cell carcinoma. The overexpression of miR-21, miR-24, and miR-31 in plasma has been reported in oral cancer. In addition, miR-181b and miR-34 overexpression has been reported in association with oral leukoplakia. Oral precancer has been linked to the under expression of miR-125b and mir-100. Sasahira et al. have shown that miR-126 might be a useful as diagnostic and therapeutic target in oral quamous cell carcinoma.
| > Inhibition of Pro-Inflammatory Pathways by Curcumin|| |
Curcumin (diferuloylmethane) is a polyphenol derived from the Curcuma longa plant, commonly known as turmeric. Curcumin has been used extensively in Ayurvedic medicine for centuries as it is nontoxic and has a variety of therapeutic properties including antioxidant, analgesic, and inflammatory and antiseptic activity. Much of the interest to medical research lies within the ability of curcumin to counteract the generation and subsequent effects of ROS and nitrogen free radicals, typically manifesting from damaged cells. Curcumin can impose desirable effects upon multiple targets within the inflammatory cascade and its related signaling pathways  [Figure 6]. It has been also known that curcumin inactivates NF-κB, an important transcription factor regulating cellular activity, particularly with respect to stress and injury. NF-κB activation appears to be crucial in the relationship between inflammation and the development of cancer. Inactivation of NF-κB by curcumin in turn leads to reduced expression of COX-2 and down-regulation of cytokines including TNF and IL and a reduction in chemokines TNF-α and NO production consequently reducing tissue damage.
|Figure 6: The multi-targeted effects of curcumin on inflammatory mediaotors|
Click here to view
Curcumin's potent anti-oxidant and free-radical quenching properties play an important role in the inhibitory effects of the compound on the initial stages of carcinogenesis. Curcumin's inhibitory effect on carcinogenesis has been demonstrated in several animal models of various tumor types including oral cancer, mammary carcinoma and intestinal tumors. It has been shown that curcumin has the ability to suppress UV irradiation-induced DNA mutagenesis. In addition to the inhibitory effects on the production of NO and the ability to scavenge DNAdamaging superoxide radicals, curcumin also affects both the Phase I and Phase II enzymes of the hepatic cytochrome p450 enzyme system involved in the oxidation and detoxification of toxic substances. Curcumin has been shown to inhibit the Phase I enzymes (including cytochrome p450 isoforms and p450 reductase) which are induced in response to toxin exposure and create a host of carcinogenic metabolites that contribute to DNA adduct formation during the oxidation of such substances. Conversely, curcumin induces the Phase II enzymes involved in detoxification of toxic metabolites (including GST, glutathione peroxidase and GR).
Current molecular pathway based therapies in clinical trials for oral squamous cell carcinoma are documented in [Figure 7]. It has been known that platinum-based agents form the backbone of the standard chemotherapeutic regimens for oral cancer. Cisplatin (cis-diamminedichloroplatinum) is a widely used drug in the class of platinum-based chemotherapies (which also includes carboplatin and oxaliplatin). The platinum compounds work by the formation of DNA crosslinks within cells, leading to apoptosis and cellular senescence. The efficacy of cisplatin in squamous cell carcinoma is greatly increased when combined with other chemotherapeutic agents, such as taxanes (paclitaxel and docetaxel) and 5-fluorouracil. There is significant interest in potentially using curcumin as an adjuvant agent in combination with standard platinum-based chemotherapy for the treatment of malignant tumors. It was also reported that CAL27 and UMSCC-1 cell lines demonstrated an increased growth suppressive effect in cells treated with a combination of liposomal curcumin and cisplatin, both in vitro as well as in mouse xenograft tumor models. Khafif et al. has also compared the effects of curcumin and single-dose radiation alone and in combination in the squamous cell carcinoma cell lines SCC-1, SCC-9, A431 and KB.In vitro growth suppression with either curcumin or radiation was observed in all the four cell lines, and the combination of both therapies resulted in an additive growth suppressive effect.
|Figure 7: Current molecular pathway based therapies in oral squamous cell carcinoma|
Click here to view
| > Conclusion|| |
The World Health Organization has emphasized recently that early detection and prevention are major objectives for reducing oral cancer cases worldwide. In India, oral cancer is a major health challenges for scientists, clinicians and policy makers. It is well said, “Prevention is better than cure and prevention is cheaper than cure”. Currently, visual cytology-based techniques and biopsy are being used by clinicians to detect dysplasia and early stage of oral squamous cell carcinoma. These approaches are limited in their ability to judge the severities of the oral lesion and are useful only after the appearance of visual changes. Therefore, tradition cytological and biopsy techniques combined with inflammatory associated molecular signatures testing would be beneficial for the efficient early detection of oral dysplastic lesion and early stages of oral squamous cell carcinoma.
| > Acknowledgments|| |
The authors would like to acknowledge the Gujarat Cancer Society and Directorate Medical Education and Research, Gujarat state for financial supports in various project related to the topic.
| > References|| |
Khan MH, Mishu MP, Imam ST. Current molecular concept of oral carcinogenesis and invasion. Med Today 2010;22:38-42.
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol 2009;45:309-16.
Mishra R. Biomarkers of oral premalignant epithelial lesions for clinical application. Oral Oncol 2012;48:578-84.
Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: Links to genetic instability. Carcinogenesis 2009;30:1073-81.
Schetter AJ, Heegaard NH, Harris CC. Inflammation and cancer: Interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis 2010;31:37-49.
Medzhitov R. Origin and physiological roles of inflammation. Nature 2008;454:428-35.
Garg A, Aggarwal BB. Nuclear transcription factor-kappaB as a target for cancer drug development. Leukemia 2002;16:1053-68.
Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science 1996;274:787-9.
Huang S, DeGuzman A, Bucana CD, Fidler IJ. Level of interleukin-8 expression by metastatic human melanoma cells directly correlates with constitutive NF-kappaB activity. Cytokines Cell Mol Ther 2000;6:9-17.
Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM, et al.
Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J Clin Invest 1997;100:2952-60.
Pontes HA, Pontes FS, Fonseca FP, de Carvalho PL, Pereira EM, de Abreu MC, et al.
Nuclear factor κB and cyclooxygenase-2 immunoexpression in oral dysplasia and oral squamous cell carcinoma. Ann Diagn Pathol 2013;17:45-50.
Meric A, Ozucer B, Gedikli O, Yildirim Y, Korkut AY, Kahya V, et al.
Impact of smoking on p65 nuclear factor κB, p38 mitogen-activated protein kinase, and inducible nitric oxide synthase expression levels in oral mucosa. J Craniofac Surg 2012;23:970-3.
Liu YC, Ho HC, Lee MR, Lai KC, Yeh CM, Lin YM, et al.
Early induction of cytokines/cytokine receptors and Co×2, and activation of NF-κB in 4-nitroquinoline 1-oxide-induced murine oral cancer model. Toxicol Appl Pharmacol 2012;262:107-16.
Liu CM, Yeh CJ, Yu CC, Chou MY, Lin CH, Wei LH, et al.
Impact of interleukin-8 gene polymorphisms and environmental factors on oral cancer susceptibility in Taiwan. Oral Dis 2012;18:307-14.
Caicedo-Granados EE, Wuertz BR, Ondrey FG. Enforced expression of nuclear factor kappa B in p53 deficient keratinocytes induces cell cycle, angiogenic potential and tumorigenesis. Oral Oncol 2012;48:303-10.
Ravi D, Ramadas K, Mathew BS, Nalinakumari KR, Nair MK, Pillai MR. Angiogenesis during tumor progression in the oral cavity is related to reduced apoptosis and high tumor cell proliferation. Oral Oncol 1998;34:543-8.
Mărgăritescu C, Pirici D, Simionescu C, Mogoantă L, Raica M, Stîngă A, et al
. VEGF and VEGFRs expression in oral squamous cell carcinoma. Rom J Morphol Embryol 2009;50:527-48.
Aonuma M, Saeki Y, Akimoto T, Nakayama Y, Hattori C, Yoshitake Y, et al.
Vascular endothelial growth factor overproduced by tumour cells acts predominantly as a potent angiogenic factor contributing to malignant progression. Int J Exp Pathol 1999;80:271-81.
dos Santos Almeida A, Oliveira DT, Pereira MC, Faustino SE, Nonogaki S, Carvalho AL, et al.
Podoplanin and VEGF-C immunoexpression in oral squamous cell carcinomas: Prognostic significance. Anticancer Res 2013;33:3969-76.
Zhao SF, Yang XD, Lu MX, Sun GW, Wang YX, Zhang YK, et al.
Prognostic significance of VEGF immunohistochemical expression in oral cancer: A meta-analysis of the literature. Tumour Biol 2013;34:3165-71.
Chien MH, Liu YF, Hsin CH, Lin CH, Shih CH, Yang SF, et al.
Impact of VEGF-C gene polymorphisms and environmental factors on oral cancer susceptibility in Taiwan. PLoS One 2013;8:e60283.
Mandal RK, Yadav SS, Panda AK, Khattri S. Vascular endothelial growth factor 936 c>T polymorphism increased oral cancer risk: Evidence from a meta-analysis. Genet Test Mol Biomarkers 2013;17:543-7.
Kapoor P, Deshmukh R. VEGF: A critical driver for angiogenesis and subsequent tumor growth: An IHC study. J Oral Maxillofac Pathol 2012;16:330-7.
Nayak S, Goel MM, Chandra S, Bhatia V, Mehrotra D, Kumar S, et al.
VEGF-A immunohistochemical and mRNA expression in tissues and its serum levels in potentially malignant oral lesions and oral squamous cell carcinomas. Oral Oncol 2012;48:233-9.
SahebJamee M, Eslami M, AtarbashiMoghadam F, Sarafnejad A. Salivary concentration of TNF alpha, IL1 alpha, IL6, and IL8 in oral squamous cell carcinoma. Med Oral Patol Oral Cir Bucal 2008;13:E292-5.
St John MA, Li Y, Zhou X, Denny P, Ho CM, Montemagno C, et al.
Interleukin 6 and interleukin 8 as potential biomarkers for oral cavity and oropharyngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2004;130:929-35.
Chen Z, Malhotra PS, Thomas GR, Ondrey FG, Duffey DC, Smith CW, et al.
Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res 1999;5:1369-79.
Wang Z, Wang C, Zhao Z, Liu F, Guan X, Lin X, et al.
Association between-251A>T polymorphism in the interleukin-8 gene and oral cancer risk: A meta-analysis. Gene 2013;522:168-76.
Suresh A, Vannan M, Kumaran D, Gümüs ZH, Sivadas P, Murugaian EE, et al.
Resistance/response molecular signature for oral tongue squamous cell carcinoma. Dis Markers 2012;32:51-64.
Pandey M, Prakash O, Santhi WS, Soumithran CS, Pillai RM. Overexpression of COX-2 gene in oral cancer is independent of stage of disease and degree of differentiation. Int J Oral Maxillofac Surg 2008;37:379-83.
Amirchaghmaghi M, Mohtasham N, Mozaffari PM. Comparison of COX2 expression between oral squamous cell carcinoma, leukoplakia and normal mucosa. J Contemp Dent Pract 2012;13:205-9.
Nagatsuka H, Siar CH, Tsujigiwa H, Naomoto Y, Han PP, Gunduz M, et al.
Heparanase and cyclooxygenase-2 gene and protein expressions during progression of oral epithelial dysplasia to carcinoma. Ann Diagn Pathol 2012;16:354-61.
Mauro A, Lipari L, Leone A, Tortorici S, Burruano F, Provenzano S, et al.
Expression of cyclooxygenase-1 and cyclooxygenase-2 in normal and pathological human oral mucosa. Folia Histochem Cytobiol 2010;48:555-63.
Prado SM, Cedrún JL, Rey RL, Villaamil VM, García AA, Ayerbes MV, et al.
Evaluation of COX-2, EGFR, and p53 as biomarkers of non-dysplastic oral leukoplakias. Exp Mol Pathol 2010;89:197-203.
Singh AK, Pandey A, Tewari M, Kumar P, Shukla HS, Pandey HP. A discussion on chemoprevention of oral cancer by selective cyclooxygenase-2 (COX-2) inhibitors. Dig J Nanomater Biostructures 2010;5:285-95.
Danielsson K, Ebrahimi M, Wahlin YB, Nylander K, Boldrup L. Increased levels of COX-2 in oral lichen planus supports an autoimmune cause of the disease. J Eur Acad Dermatol Venereol 2012;26:1415-9.
Wang YH, Wu MW, Yang AK, Zhang WD, Sun J, Liu TR, et al.
COX-2 Gene increases tongue cancer cell proliferation and invasion through VEGF-C pathway. Med Oncol 2011;28 Suppl 1:S360-6.
Ryott M, Marklund L, Wangsa D, Elmberger G, Munck-Wikland E. Cyclooxygenase-2 expression in oral tongue squamous cell carcinoma. J Oral Pathol Med 2011;40:385-9.
Patel JB, Shukla SN, Patel HR, Kothari KK, Shah PM, Patel PS. Utility of urinary biomarkers in oral cancer. Asian Pac J Cancer Prev 2007;8:229-35.
Kim PM, Wells PG. Genoprotection by UDP-glucuronosyltransferases in peroxidase-dependent, reactive oxygen species-mediated micronucleus initiation by the carcinogens 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and benzo[a] pyrene. Cancer Res 1996;56:1526-32.
Kosaka T, Miyata A, Ihara H, Hara S, Sugimoto T, Takeda O, et al.
Characterization of the human gene (PTGS2) encoding prostaglandin-endoperoxide synthase 2. Eur J Biochem 1994;221:889-97.
Sen CK, Packer L. Antioxidant and redox regulation of gene transcription. FASEB J 1996;10:709-20.
Rioux N, Castonguay A. The induction of cyclooxygenase-1 by a tobacco carcinogen in U937 human macrophages is correlated to the activation of NF-kappaB. Carcinogenesis 2000;21:1745-51.
Wallace JM. Nutritional and botanical modulation of the inflammatory cascade – eicosanoids, cyclooxygenases, and lipoxygenases – as an adjunct in cancer therapy. Integr Cancer Ther 2002;1:7-37.
Sawhney M, Rohatgi N, Kaur J, Shishodia S, Sethi G, Gupta SD, et al.
Expression of NF-kappaB parallels COX-2 expression in oral precancer and cancer: Association with smokeless tobacco. Int J Cancer 2007;120:2545-56.
Rioux N, Castonguay A. Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicylic acid and NS-398. Cancer Res 1998;58:5354-60.
Jeng JH, Ho YS, Chan CP, Wang YJ, Hahn LJ, Lei D, et al.
Areca nut extract up-regulates prostaglandin production, cyclooxygenase-2 mRNA and protein expression of human oral keratinocytes. Carcinogenesis 2000;21:1365-70.
Fan CC, Wang TY, Cheng YA, Jiang SS, Cheng CW, Lee AY, et al.
Expression of E-cadherin, Twist, and p53 and their prognostic value in patients with oral squamous cell carcinoma. J Cancer Res Clin Oncol 2013;139:1735-44.
Cui JJ, Han XL, Wang WM. Expression and significance of p53 and mdm2 in patients with leukoplakia cancer. Asian Pac J Trop Med 2013;6:831-4.
Bascones-Martínez A, López-Durán M, Cano-Sánchez J, Sánchez-Verde L, Díez-Rodríguez A, Aguirre-Echebarría P, et al.
Differences in the expression of five senescence markers in oral cancer, oral leukoplakia and control samples in humans. Oncol Lett 2012;3:1319-25.
Cutilli T, Leocata P, Dolo V, Altobelli E. Evaluation of p53 protein as a prognostic factor for oral cancer surgery. Br J Oral Maxillofac Surg 2013;51:922-7.
Patel KR, Vajaria BN, Begum R, Shah FD, Patel JB, Shukla SN, et al.
Association between p53 gene variants and oral cancer susceptibility in population from Gujarat, West India. Asian Pac J Cancer Prev 2013;14:1093-100.
Jing G, Lv K, Jiao X. The p53 codon 72 polymorphism and the risk of oral cancer in a Chinese Han population. Genet Test Mol Biomarkers 2012;16:1149-52.
Reddy VM, Kamath A, Radhakrishnan RA. p53 immunoprofiling of potentially malignant oral disorders: A case series analysis. Indian J Cancer 2012;49:27-32.
Choudhari SK, Chaudhary M, Bagde S, Gadbail AR, Joshi V. Nitric oxide and cancer: A review. World J Surg Oncol 2013;11:118.
Ou Yang KX, Liang J, Huang ZQ. Association of clinicopathologic parameters with the expression of inducible nitric oxide synthase and vascular endothelial growth factor in mucoepidermoid carcinoma. Oral Dis 2011;17:590-6.
Choudhari SK, Sridharan G, Gadbail A, Poornima V. Nitric oxide and oral cancer: A review. Oral Oncol 2012;48:475-83.
Patel JB, Shah FD, Shukla SN, Shah PM, Patel PS. Role of nitric oxide and antioxidant enzymes in the pathogenesis of oral cancer. J Cancer Res Ther 2009;5:247-53.
Murata J, Tada M, Iggo RD, Sawamura Y, Shinohe Y, Abe H. Nitric oxide as a carcinogen: Analysis by yeast functional assay of inactivating p53 mutations induced by nitric oxide. Mutat Res 1997;379:211-8.
Lala PK, Chakraborty C. Role of nitric oxide in carcinogenesis and tumour progression. Lancet Oncol 2001;2:149-56.
Gallo O, Sardi I, Masini M, Franchi A. Re: Relationship between p53 mutations and inducible nitric oxide synthase expression in human colorectal cancer. J Natl Cancer Inst 1999;91:1509-11.
Hofseth LJ. The adaptive imbalance to genotoxic stress: Genome guardians rear their ugly heads. Carcinogenesis 2004;25:1787-93.
Wlodek L. Beneficial and harmful effects of thiols. Pol J Pharmacol 2002;54:215-23.
Singh RD, Haridas N, Shah FD, Patel JB, Shukla SN, Patel PS. Gene polymorphisms, tobacco exposure and oral cancer susceptibility: A study from Gujarat, West India. Oral Dis 2014;20:84-93.
Zhang Y, Yu Q, Yu W, Hu M. Glutathione S-transferase M1 null genotype is associated with increased risk of oral cancer in East Asians: A meta-analysis. Tumour Biol 2013;34:3183-8.
Dong G, Tian Y, Chen S, Xu X, Zheng J, Li T. Glutathione S-transferase T1 null genotype is associated with oral cancer susceptibility in Asian populations. Tumour Biol 2013;34:1753-7.
Mondal R, Ghosh SK, Talukdar FR, Laskar RS. Association of mitochondrial D-loop mutations with GSTM1 and GSTT1 polymorphisms in oral carcinoma: A case control study from Northeast India. Oral Oncol 2013;49:345-53.
Naga Sirisha CV, Manohar RM. Study of antioxidant enzymes superoxide dismutase and glutathione peroxidase levels in tobacco chewers and smokers: A pilot study. J Cancer Res Ther 2013;9:210-4.
Mahimkar MB, Samant TA, Kannan S, Tulsulkar J, Pai PS, Anantharaman D. Polymorphisms in GSTM1 and XPD genes predict clinical outcome in advanced oral cancer patients treated with postoperative radiotherapy. Mol Carcinog 2012;51 Suppl 1:E94-103.
Chitra S, Balasubramaniam M, Hazra J. Effect of a-tocopherol on salivary reactive oxygen species and trace elements in oral submucous fibrosis. Ann Clin Biochem 2012;49:262-5.
Gurudath S, Ganapathy KS, Pai A, Ballal S, Ml A. Estimation of superoxide dismutase and glutathione peroxidase in oral submucous fibrosis, oral leukoplakia and oral cancer – a comparative study. Asian Pac J Cancer Prev 2012;13:4409-12.
Vlková B, Stanko P, Minárik G, Tóthová L, Szemes T, Banasová L, et al.
Salivary markers of oxidative stress in patients with oral premalignant lesions. Arch Oral Biol 2012;57:1651-6.
Wu SH, Lee KW, Chen CH, Lin CC, Tseng YM, Ma H, et al.
Epistasis of oxidative stress-related enzyme genes on modulating the risks in oral cavity cancer. Clin Chim Acta 2010;411:1705-10.
Patel BP, Rawal UM, Rawal RM, Shukla SN, Patel PS. Tobacco, antioxidant enzymes, oxidative stress, and genetic susceptibility in oral cancer. Am J Clin Oncol 2008;31:454-9.
Sasahira T, Kurihara M, Bhawal UK, Ueda N, Shimomoto T, Yamamoto K, et al.
Downregulation of miR-126 induces angiogenesis and lymphangiogenesis by activation of VEGF-A in oral cancer. Br J Cancer 2012;107:700-6.
Irving GR, Karmokar A, Berry DP, Brown K, Steward WP. Curcumin: The potential for efficacy in gastrointestinal diseases. Best Pract Res Clin Gastroenterol 2011;25:519-34.
Wilken R, Veena MS, Wang MB, Srivatsan ES. Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. Mol Cancer 2011;10:12.
Thapliyal R, Maru GB. Inhibition of cytochrome P450 isozymes by curcumins in vitro
and in vivo
. Food Chem Toxicol 2001;39:541-7.
Iqbal M, Sharma SD, Okazaki Y, Fujisawa M, Okada S. Dietary supplementation of curcumin enhances antioxidant and phase II metabolizing enzymes in ddY male mice: Possible role in protection against chemical carcinogenesis and toxicity. Pharmacol Toxicol 2003;92:33-8.
Khafif A, Lev-Ari S, Vexler A, Barnea I, Starr A, Karaush V, et al.
Curcumin: A potential radio-enhancer in head and neck cancer. Laryngoscope 2009;119:2019-26.
Rath GK. Molecular markers in the head and neck cancers: Are we there yet? J Cancer Res Ther 2013;9:1-2.
[Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5], [Figure 6], [Figure 7]
[Table 1], [Table 2], [Table 3], [Table 4], [Table 5]